Literature DB >> 18614917

Low prevalence of detectable HIV plasma viremia in patients treated with antiretroviral therapy in Burkina Faso and Mali.

Catherine Boileau1, Vinh-Kim Nguyen, Mohamed Sylla, Nima Machouf, Annie Chamberland, Hamar A Traoré, Pascal A Niamba, Ismaël Diallo, Moussa Maïga, Mamadou Cissé, Sélim Rashed, Cécile Tremblay.   

Abstract

BACKGROUND: Sub-Saharan Africa has seen dramatic increases in the numbers of people treated with antiretroviral therapy (ART). Although standard ART regimens are now universally applied, viral load measurement is not currently part of standard monitoring protocols in sub-Saharan Africa.
METHODS: We describe the prevalence of inadequate virological response (IVR) to ART (viral load >or= 500 copies/mL) and identify factors associated with this outcome in 606 HIV-positive patients treated for at least 6 months. Recruitment took place in 7 hospitals and community-based sites in Bamako and Ouagadougou, and information was collected using medical charts and interviews.
RESULTS: The overall prevalence of IVR in treatment-naive patients was 12.3% and 24.4% for pretreated patients. There were no differences in rates of IVR according to ART delivery sites and time on treatment. Patients living farther away [odds ratio (OR) = 2.48; 95% confidence interval (CI) 1.40 to 4.39], those on protease inhibitor or nucleoside reverse transcriptase inhibitor regimens (OR = 3.23; 95% CI 1.79 to 5.82) and those reporting treatment interruptions (OR = 2.36; 95% CI 1.35 to 4.15), had increased odds of IVR. Immune suppression (OR = 3.32, 95% CI 1.94 to 5.70) and poor self-rated health (OR = 2.00; 95% CI 1.17 to 3.41) were also associated with IVR.
CONCLUSIONS: Sufficient expertise and dedication exist in public hospital and community-based programs to achieve rates of treatment success comparable to better-resourced settings.

Entities:  

Mesh:

Year:  2008        PMID: 18614917     DOI: 10.1097/QAI.0b013e31817dc416

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  13 in total

1.  Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.

Authors:  B Chaplin; G Eisen; J Idoko; D Onwujekwe; E Idigbe; I Adewole; W Gashau; S Meloni; A D Sarr; J L Sankalé; E Ekong; R L Murphy; P Kanki
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-21       Impact factor: 2.205

2.  First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration.

Authors:  Julia Drylewicz; Serge Eholie; Moussa Maiga; Djimon Marcel Zannou; Papa Salif Sow; Didier K Ekouevi; Kevin Peterson; Emmanuel Bissagnene; François Dabis; Rodolphe Thiébaut
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

3.  Quality of HIV care provided by non-physician clinicians and physicians in Mozambique: a retrospective cohort study.

Authors:  Kenneth H Sherr; Mark A Micek; Sarah O Gimbel; Stephen S Gloyd; James P Hughes; Grace C John-Stewart; Rosa M Manjate; James Pfeiffer; Noel S Weiss
Journal:  AIDS       Date:  2010-01       Impact factor: 4.177

4.  A qualitative study of patient motivation to adhere to combination antiretroviral therapy in South Africa.

Authors:  Francois van Loggerenberg; Debra Gray; Santhanalakshmi Gengiah; Pinky Kunene; Tanuja N Gengiah; Kogieleum Naidoo; Alison D Grant
Journal:  AIDS Patient Care STDS       Date:  2015-02-18       Impact factor: 5.078

5.  Molecular Epidemiology of Human Herpes Virus Type 8 Among Patients with Compromised Immune System in Ouagadougou, Burkina Faso.

Authors:  Nakougou Moϊ-Bohm Biatougou; Muriel S Ouedraogo; Serge Theophile Soubeiga; Theodora Mahoukede Zohoncon; Paul Ouedraogo; Dorcas Obiri-Yeboah; Aziz Sidi Aristide Tapsoba; Touwendpoulimdé Isabelle Kiendrebeogo; Tani Sagna; Pascal Niamba; Adama Traore; Jacques Simpore
Journal:  HIV AIDS (Auckl)       Date:  2022-07-08

6.  Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China.

Authors:  Ye Ma; Decai Zhao; Lan Yu; Marc Bulterys; Matthew L Robinson; Yan Zhao; Zhihui Dou; Philippe Chiliade; Xiaoyu Wei; Fujie Zhang
Journal:  Clin Infect Dis       Date:  2010-01-15       Impact factor: 9.079

7.  Antiretroviral (ARV) Therapy in Resource Poor Countries: What do we Need in Real Life?

Authors:  Francesco Castelli; Virginio Pietra; Ismael Diallo; Richard F Schumacher; Jacques Simpore
Journal:  Open AIDS J       Date:  2010-01-19

8.  Long-term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa.

Authors:  Charlotte Huet; Abdoulaye Ouedraogo; Issouf Konaté; Isidore Traore; François Rouet; Antoinette Kaboré; Anselme Sanon; Philippe Mayaud; Philippe Van de Perre; Nicolas Nagot
Journal:  BMC Public Health       Date:  2011-09-14       Impact factor: 3.295

9.  Outcomes of antiretroviral treatment in HIV-infected adults: a dynamic and observational cohort study in Shenzhen, China, 2003-2014.

Authors:  Peng Huang; Jingguang Tan; Wenzhe Ma; Hui Zheng; Yan Lu; Ning Wang; Zhihang Peng; Rongbin Yu
Journal:  BMJ Open       Date:  2015-05-22       Impact factor: 2.692

10.  Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal.

Authors:  Elena Losina; Hapsatou Touré; Lauren M Uhler; Xavier Anglaret; A David Paltiel; Eric Balestre; Rochelle P Walensky; Eugène Messou; Milton C Weinstein; François Dabis; Kenneth A Freedberg
Journal:  PLoS Med       Date:  2009-10-27       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.